Risk-Adapted Adjuvant Radiation treatment After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Strategy to Patients Using Resectable CT3-4 or perhaps N+ Anus Cancer malignancy: Five-Year Disease-Free Tactical Link between the Single-Center Sequence.